Head-to-head evidence
exidavnemab vs UB-312
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: alpha-synuclein · full Parkinson's Disease pipeline
exidavnemab
Developed by BioArctic AB
NCT06671938 · Phase 2 · completed
This is a randomized, double-blind, placebo-controlled trial, but it enrolled only 38 participants split across dose cohorts, its primary endpoint measures adverse-event incidence rather than efficacy, and results have not yet been posted, so no conclusion about benefit can be drawn.
UB-312
Developed by Vaxxinity
NCT04075318 · Phase 1 · completed
A randomized, quadruple-blind, placebo-controlled phase 1 study of the UB-312 vaccine in 70 participants. The design is sound but small, and its primary measures were safety and immunogenicity: anti-alpha-synuclein antibody responses were reported in blood while cerebrospinal-fluid responses were only partial, with no statistical analyses posted, so the primary outcomes read as mixed.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: exidavnemab's landscape · UB-312's landscape